1. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side effects from 33 randomised controlled trials;Yusuf, S.; Collins, R.; Peto, R.; Furberg, C.; Stampfer, M.J.; Goldhaber, S.Z.; Hennekens, C.H.;Eur HeartJ,1985
2. Gruppo Italiano per lo Studio della Streptochinas; nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction;Lancet,1986
3. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase;Chesebro, J.H.; Knatterud, G.; Roberts, R.; Borer, J.; Cohen, L.S.; Dodge, H.T.;Circulation,1987
4. Second International Study of Infarct Survival (ISIS-2) study group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among;Lancet; cases of suspected acute myocardial infarction: ISIS-2,1988
5. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function;de Werf F, Van;Lancet,1989